Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
Cullinan Therapeutics announced it will host a virtual event on September 14, 2026, to discuss Phase 3 REZILIENT3 trial results for zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC. The trial met its primary endpoint of progression-free survival at the planned interim analysis, with results to be presented at the IASLC 2026 World Conference on Lung Cancer.